TFL Gallery / t-disposition
DST01 · Table
Subject Disposition
Screened, randomised, treated, completed and discontinued counts with reasons for discontinuation, over the ITT set.
- Slug
- t-disposition
- Regulatory ID
- DST01
- Type
- Table
- E3 position
- §14.1
- Status
- evidenced
- Current iteration
- v003
- Datasets
- adsl 70c7278
- Evidence
- 19/19 passing
- Requirements
- DSP-ALL-001 DSP-ALL-002 DSP-DISP-001 DSP-DISP-002 DSP-INTXT-001 DSP-INTXT-002 DSP-INTXT-003 STD-GATE-001 STD-GATE-002 STD-GATE-003 STD-GATE-004 STD-GATE-005 STD-MODEL-001 STD-MODEL-002 STD-MODEL-003 STD-MODEL-004 STD-MODEL-005 STD-SRC-001 STD-SRC-002
- Used in
- Clinical Study Report Table 14.1.1
- Study Synopsis Table 13.1
- Post-Text Display Package Table 14.1.1
- Abbreviated Clinical Study Report (ICH E3) Table 14.1.1
- Study model
- Intent-to-Treat Population ITTFL · grouped by TRT01A
- Specification
- 3 iterations
- Environment
- R 4.3.3 Darwin 23.6.0
- adsl254 rows · 70c7278
- analysis.yamlwhat to compute
- display.yamlhow to show it
- study modelIntent-to-Treat Population
- prepare_data()regenerate('t-disposition')
- build_ard()one row per statistic
- render_display()every variant
- render_rtf()the same cells
- ard.jsonv003 · 84 rows · 5a073a0
- table.htmlthe rendered display
- table.rtfsha256 6579d64
- table-in-text.rtfsha256 8d38ef3
- manifest.jsonwho, why, every hash
Generated by the same pipeline run that wrote the ARD and the HTML above, from the same rendered cells; the short hash is the manifest's record of the file.
| Subject Disposition | ||||
| Study CDISCPILOT01 — Intent-to-Treat Analysis Set | ||||
| Placebo (N=86) | Xanomeline Low Dose (N=84) | Xanomeline High Dose (N=84) | Total (N=254) | |
|---|---|---|---|---|
| Disposition, n (%) | ||||
| Subjects randomised | ||||
| Subjects treated | ||||
| Completed the study | ||||
| Discontinued the study | ||||
| Reason for discontinuation, n (%) | ||||
| Death | ||||
| Other / not specified | ||||
| Deaths, n (%) | ||||
| Died on study | ||||
| Percentages are based on the number of randomised subjects in each treatment group. | ||||
| The ADSL shipped in pharmaverseadam carries no DCSREAS/DCDECOD, so the reason for discontinuation is derived: 'Death' where DTHFL = 'Y', otherwise 'Other / not specified'. | ||||
| 52 screen failures are excluded from every analysis dataset. | ||||
| Source: adsl (CDISCPILOT01 ADaM package, phuse-org/phuse-scripts). Data cut-off: 2014-07-01. | ||||
| open.csr display t-disposition (post_text variant); generated from the committed ARD. | ||||
Rendered from outputs/t-disposition/v003/table.html.
| analysis | group1 | group1_level | group2 | group2_level | variable | variable_level | context | stat_name | stat_label | warning | error | stat |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| randomised | TRT01A | Placebo | — | — | RANDFL | Y | subject_count | n | n | — | — | 86 |
| randomised | TRT01A | Placebo | — | — | RANDFL | Y | subject_count | N | N | — | — | 86 |
| randomised | TRT01A | Placebo | — | — | RANDFL | Y | subject_count | p | % | — | — | 1 |
| randomised | TRT01A | Xanomeline Low Dose | — | — | RANDFL | Y | subject_count | n | n | — | — | 84 |
| randomised | TRT01A | Xanomeline Low Dose | — | — | RANDFL | Y | subject_count | N | N | — | — | 84 |
| randomised | TRT01A | Xanomeline Low Dose | — | — | RANDFL | Y | subject_count | p | % | — | — | 1 |
| randomised | TRT01A | Xanomeline High Dose | — | — | RANDFL | Y | subject_count | n | n | — | — | 84 |
| randomised | TRT01A | Xanomeline High Dose | — | — | RANDFL | Y | subject_count | N | N | — | — | 84 |
| randomised | TRT01A | Xanomeline High Dose | — | — | RANDFL | Y | subject_count | p | % | — | — | 1 |
| randomised | TRT01A | Total | — | — | RANDFL | Y | subject_count | n | n | — | — | 254 |
| randomised | TRT01A | Total | — | — | RANDFL | Y | subject_count | N | N | — | — | 254 |
| randomised | TRT01A | Total | — | — | RANDFL | Y | subject_count | p | % | — | — | 1 |
| treated | TRT01A | Placebo | — | — | SAFFL | Y | subject_count | n | n | — | — | 86 |
| treated | TRT01A | Placebo | — | — | SAFFL | Y | subject_count | N | N | — | — | 86 |
| treated | TRT01A | Placebo | — | — | SAFFL | Y | subject_count | p | % | — | — | 1 |
| treated | TRT01A | Xanomeline Low Dose | — | — | SAFFL | Y | subject_count | n | n | — | — | 84 |
| treated | TRT01A | Xanomeline Low Dose | — | — | SAFFL | Y | subject_count | N | N | — | — | 84 |
| treated | TRT01A | Xanomeline Low Dose | — | — | SAFFL | Y | subject_count | p | % | — | — | 1 |
| treated | TRT01A | Xanomeline High Dose | — | — | SAFFL | Y | subject_count | n | n | — | — | 84 |
| treated | TRT01A | Xanomeline High Dose | — | — | SAFFL | Y | subject_count | N | N | — | — | 84 |
| treated | TRT01A | Xanomeline High Dose | — | — | SAFFL | Y | subject_count | p | % | — | — | 1 |
| treated | TRT01A | Total | — | — | SAFFL | Y | subject_count | n | n | — | — | 254 |
| treated | TRT01A | Total | — | — | SAFFL | Y | subject_count | N | N | — | — | 254 |
| treated | TRT01A | Total | — | — | SAFFL | Y | subject_count | p | % | — | — | 1 |
| completed | TRT01A | Placebo | — | — | COMPLFL | Y | subject_count | n | n | — | — | 58 |
| completed | TRT01A | Placebo | — | — | COMPLFL | Y | subject_count | N | N | — | — | 86 |
| completed | TRT01A | Placebo | — | — | COMPLFL | Y | subject_count | p | % | — | — | 0.674418604651163 |
| completed | TRT01A | Xanomeline Low Dose | — | — | COMPLFL | Y | subject_count | n | n | — | — | 25 |
| completed | TRT01A | Xanomeline Low Dose | — | — | COMPLFL | Y | subject_count | N | N | — | — | 84 |
| completed | TRT01A | Xanomeline Low Dose | — | — | COMPLFL | Y | subject_count | p | % | — | — | 0.297619047619048 |
| completed | TRT01A | Xanomeline High Dose | — | — | COMPLFL | Y | subject_count | n | n | — | — | 27 |
| completed | TRT01A | Xanomeline High Dose | — | — | COMPLFL | Y | subject_count | N | N | — | — | 84 |
| completed | TRT01A | Xanomeline High Dose | — | — | COMPLFL | Y | subject_count | p | % | — | — | 0.321428571428571 |
| completed | TRT01A | Total | — | — | COMPLFL | Y | subject_count | n | n | — | — | 110 |
| completed | TRT01A | Total | — | — | COMPLFL | Y | subject_count | N | N | — | — | 254 |
| completed | TRT01A | Total | — | — | COMPLFL | Y | subject_count | p | % | — | — | 0.433070866141732 |
| discontinued | TRT01A | Placebo | — | — | DISCFL | Y | subject_count | n | n | — | — | 28 |
| discontinued | TRT01A | Placebo | — | — | DISCFL | Y | subject_count | N | N | — | — | 86 |
| discontinued | TRT01A | Placebo | — | — | DISCFL | Y | subject_count | p | % | — | — | 0.325581395348837 |
| discontinued | TRT01A | Xanomeline Low Dose | — | — | DISCFL | Y | subject_count | n | n | — | — | 59 |
| discontinued | TRT01A | Xanomeline Low Dose | — | — | DISCFL | Y | subject_count | N | N | — | — | 84 |
| discontinued | TRT01A | Xanomeline Low Dose | — | — | DISCFL | Y | subject_count | p | % | — | — | 0.702380952380952 |
| discontinued | TRT01A | Xanomeline High Dose | — | — | DISCFL | Y | subject_count | n | n | — | — | 57 |
| discontinued | TRT01A | Xanomeline High Dose | — | — | DISCFL | Y | subject_count | N | N | — | — | 84 |
| discontinued | TRT01A | Xanomeline High Dose | — | — | DISCFL | Y | subject_count | p | % | — | — | 0.678571428571429 |
| discontinued | TRT01A | Total | — | — | DISCFL | Y | subject_count | n | n | — | — | 144 |
| discontinued | TRT01A | Total | — | — | DISCFL | Y | subject_count | N | N | — | — | 254 |
| discontinued | TRT01A | Total | — | — | DISCFL | Y | subject_count | p | % | — | — | 0.566929133858268 |
| disc_death | TRT01A | Placebo | — | — | DISCREAS | Y | subject_count | n | n | — | — | 2 |
| disc_death | TRT01A | Placebo | — | — | DISCREAS | Y | subject_count | N | N | — | — | 86 |
| disc_death | TRT01A | Placebo | — | — | DISCREAS | Y | subject_count | p | % | — | — | 0.0232558139534884 |
| disc_death | TRT01A | Xanomeline Low Dose | — | — | DISCREAS | Y | subject_count | n | n | — | — | 1 |
| disc_death | TRT01A | Xanomeline Low Dose | — | — | DISCREAS | Y | subject_count | N | N | — | — | 84 |
| disc_death | TRT01A | Xanomeline Low Dose | — | — | DISCREAS | Y | subject_count | p | % | — | — | 0.0119047619047619 |
| disc_death | TRT01A | Xanomeline High Dose | — | — | DISCREAS | Y | subject_count | n | n | — | — | 0 |
| disc_death | TRT01A | Xanomeline High Dose | — | — | DISCREAS | Y | subject_count | N | N | — | — | 84 |
| disc_death | TRT01A | Xanomeline High Dose | — | — | DISCREAS | Y | subject_count | p | % | — | — | 0 |
| disc_death | TRT01A | Total | — | — | DISCREAS | Y | subject_count | n | n | — | — | 3 |
| disc_death | TRT01A | Total | — | — | DISCREAS | Y | subject_count | N | N | — | — | 254 |
| disc_death | TRT01A | Total | — | — | DISCREAS | Y | subject_count | p | % | — | — | 0.0118110236220472 |
| disc_other | TRT01A | Placebo | — | — | DISCREAS | Y | subject_count | n | n | — | — | 26 |
| disc_other | TRT01A | Placebo | — | — | DISCREAS | Y | subject_count | N | N | — | — | 86 |
| disc_other | TRT01A | Placebo | — | — | DISCREAS | Y | subject_count | p | % | — | — | 0.302325581395349 |
| disc_other | TRT01A | Xanomeline Low Dose | — | — | DISCREAS | Y | subject_count | n | n | — | — | 58 |
| disc_other | TRT01A | Xanomeline Low Dose | — | — | DISCREAS | Y | subject_count | N | N | — | — | 84 |
| disc_other | TRT01A | Xanomeline Low Dose | — | — | DISCREAS | Y | subject_count | p | % | — | — | 0.69047619047619 |
| disc_other | TRT01A | Xanomeline High Dose | — | — | DISCREAS | Y | subject_count | n | n | — | — | 57 |
| disc_other | TRT01A | Xanomeline High Dose | — | — | DISCREAS | Y | subject_count | N | N | — | — | 84 |
| disc_other | TRT01A | Xanomeline High Dose | — | — | DISCREAS | Y | subject_count | p | % | — | — | 0.678571428571429 |
| disc_other | TRT01A | Total | — | — | DISCREAS | Y | subject_count | n | n | — | — | 141 |
| disc_other | TRT01A | Total | — | — | DISCREAS | Y | subject_count | N | N | — | — | 254 |
| disc_other | TRT01A | Total | — | — | DISCREAS | Y | subject_count | p | % | — | — | 0.55511811023622 |
| died | TRT01A | Placebo | — | — | DTHFL | Y | subject_count | n | n | — | — | 2 |
| died | TRT01A | Placebo | — | — | DTHFL | Y | subject_count | N | N | — | — | 86 |
| died | TRT01A | Placebo | — | — | DTHFL | Y | subject_count | p | % | — | — | 0.0232558139534884 |
| died | TRT01A | Xanomeline Low Dose | — | — | DTHFL | Y | subject_count | n | n | — | — | 1 |
| died | TRT01A | Xanomeline Low Dose | — | — | DTHFL | Y | subject_count | N | N | — | — | 84 |
| died | TRT01A | Xanomeline Low Dose | — | — | DTHFL | Y | subject_count | p | % | — | — | 0.0119047619047619 |
| died | TRT01A | Xanomeline High Dose | — | — | DTHFL | Y | subject_count | n | n | — | — | 0 |
| died | TRT01A | Xanomeline High Dose | — | — | DTHFL | Y | subject_count | N | N | — | — | 84 |
| died | TRT01A | Xanomeline High Dose | — | — | DTHFL | Y | subject_count | p | % | — | — | 0 |
| died | TRT01A | Total | — | — | DTHFL | Y | subject_count | n | n | — | — | 3 |
| died | TRT01A | Total | — | — | DTHFL | Y | subject_count | N | N | — | — | 254 |
| died | TRT01A | Total | — | — | DTHFL | Y | subject_count | p | % | — | — | 0.0118110236220472 |
84 rows, one per computed statistic.
- Schema
- opencsr/ard/v1
- Generated
- 2026-09-02T15:19:12Z
- Spec hash
- sha256:8c432e510cf8fe58349f0315cb25c51231c261a2276707cfd7168cd064a3d62d
- Display hash
- sha256:c00f24720932be1d3c05e8af6faef5feaec615578a2da9ebd5ea8b145d5a9a1b
- ARD file
- outputs/t-disposition/v003/ard.json
- ARD hash
- sha256:5a073a0a558678bc67b89573bc98619270f854d3af5d5cbdc18cd0ce8ed4f530
Source datasets
| Dataset | Rows | Package | Hash |
|---|---|---|---|
| adsl | 254 | phuse-org/phuse-scripts:data/adam 398a6d33ced9359ffb58c46650a6d488811176b1 | sha256:70c7278e83e571a7d4a94fd864c98bf8ca243c7c2cc9eec8b99a40fa7bc98e35 |
Environment
R 4.3.3 · Darwin 23.6.0 · cards 0.6.1 · cardx 0.2.5 · gtsummary 2.3.0 · gt 1.0.0 · dplyr 1.1.4 · pharmaverseadam 1.1.0 · jsonlite 2.0.0 · yaml 2.3.10 · digest 0.6.37
id: t-disposition
title: "Subject Disposition"
regulatory_id: DST01
type: table
dataset: adsl
analysis_set: itt
denominator: adsl
group:
- TRT01A
total: true
analyses:
- name: randomised
method: subject_count
label: "Subjects randomised"
variable: RANDFL
filter: null
- name: treated
method: subject_count
label: "Subjects treated"
variable: SAFFL
filter: "SAFFL == 'Y'"
- name: completed
method: subject_count
label: "Completed the study"
variable: COMPLFL
filter: "COMPLFL == 'Y'"
- name: discontinued
method: subject_count
label: "Discontinued the study"
variable: DISCFL
filter: "COMPLFL == 'N'"
- name: disc_death
method: subject_count
label: "Discontinued: death"
variable: DISCREAS
filter: "!is.na(DISCREAS) & DISCREAS == 'Death'"
- name: disc_other
method: subject_count
label: "Discontinued: other / not specified"
variable: DISCREAS
filter: "!is.na(DISCREAS) & DISCREAS == 'Other/Not specified'"
- name: died
method: subject_count
label: "Died"
variable: DTHFL
filter: "!is.na(DTHFL) & DTHFL == 'Y'"
id: t-disposition
title: "Subject Disposition"
study: CDISCPILOT01
population_label: "Intent-to-Treat Analysis Set"
cutoff: "2014-07-01"
source: "Source: adsl (CDISCPILOT01 ADaM package, phuse-org/phuse-scripts). Data cut-off: 2014-07-01."
footnotes:
- "Percentages are based on the number of randomised subjects in each treatment group."
- "The ADSL shipped in pharmaverseadam carries no DCSREAS/DCDECOD, so the reason for discontinuation is derived: 'Death' where DTHFL = 'Y', otherwise 'Other / not specified'."
- "52 screen failures are excluded from every analysis dataset."
columns:
order: [Placebo, "Xanomeline Low Dose", "Xanomeline High Dose", Total]
format:
digits:
p: 1
rows:
- { label: "Disposition, n (%)", section: true }
- { analysis: randomised, label: "Subjects randomised", pattern: n_pct, indent: 1 }
- { analysis: treated, label: "Subjects treated", pattern: n_pct, indent: 1 }
- { analysis: completed, label: "Completed the study", pattern: n_pct, indent: 1 }
- { analysis: discontinued, label: "Discontinued the study", pattern: n_pct, indent: 1 }
- { label: "Reason for discontinuation, n (%)", section: true }
- { analysis: disc_death, label: "Death", pattern: n_pct, indent: 1 }
- { analysis: disc_other, label: "Other / not specified", pattern: n_pct, indent: 1 }
- { label: "Deaths, n (%)", section: true }
- { analysis: died, label: "Died on study", pattern: n_pct, indent: 1 }
variants:
post_text: {}
in_text:
title: "Subject Disposition (Summary)"
v003current
One study (D0032 R2, #60): read the CDISC pilot own ADaM package, which assigns every subject the arm the rest of the report uses. Spec unchanged; lane changed.
2026-09-02T15:19:12Z · @obotclaw
v002
Add submission-format RTF artifacts to every variant (obot.roadmap #129 A).
2026-07-27T03:23:35Z · @obotclaw
v001
Initial generation of DST01 from the statistical analysis plan shell.
2026-07-25T06:39:07Z · @jwildfire
Every iteration is kept: outputs/t-disposition/vNNN/ holds the spec snapshot, the ARD, the rendered output, and a manifest recording who regenerated it, why, and from which commit.